# Post-transplant lymphoproliferative disorder

The EU has approved 1 indication of 1 drug in post-transplant lymphoproliferative disorder. It needs a biomarker result: EBV (1).

## Approved indications

### EBV

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Tabelecleucel](https://oncolabels.com/drugs/tabelecleucel) (Ebvallo) | EBV-positive | Monotherapy | 2nd line | After at least one prior therapy (for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate); Aged 2 years and older |

## Label wording

- **Tabelecleucel** (Ebvallo), Post-transplant lymphoproliferative disorder, 2nd line: “Ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/ebvallo-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/post-transplant-lymphoproliferative-disorder